Company*
(Country; Symbol)		 Company*
(Country; Symbol)		 Type/Product Area Terms/Details (Date)
Amsterdam Molecular Therapeutics BV* (the Netherlands) Digna Biotech SL* (Spain) Licensing agreement to commercialize gene therapy products developed at the Center for the Study of Applied Medicine at the University of Navarra, Spain AMT plans to start preclinical studies next year on the first program, an adeno-associated viral vector delivering insulin-like growth factor I for late-stage liver cirrhosis (11/27)
Arius Research Inc. (Canada; TSX:ARI) Avid Bioservices Inc.* Manufacturing supply and technology transfer agreement covering Arius' lead cancer stem cell antibody targeting an epitope of CD44 found in breast, colon and prostate cancers Avid will begin manufacturing a supply of the drug for human trials, expected to start in 2008 (12/5)
Binex Co. Ltd.* (South Korea) MaxCyte Inc.* Sponsored research agreement to evaluate MaxCyte's GMP-compliant cell-loading technology for use in the closed-system manufacturing of Binex's cell-based cancer immunotherapies The deal provides Binex an option to license MaxCyte's technology for clinical and commercial use in Korea (11/30)
BioAlliance Pharma SA (France; PARIS:BIO) Immtech Pharmaceuticals Inc. (AMEX:IMM) Exclusive licensing agreement granting BioAlliance European commercialization rights to pafuramidine maleate Immtech will receive an initial license fee of $3M and stands to earn a further $13M in milestone payments if pafuramidine obtains regulatory approval in Europe; the U.S. company also will receive "significant" royalties and possibly two additional milestone payments linked to the value of sales (12/12**)
BioView Ltd.* Transgenomic Inc. (OTC BB:TBIO) Agreement to distribute BioView's family of Scanning and Analysis Workstations in selected Western European countries and Scandinavia Transgenomic's European sales and support organization will market, sell and serve the instruments (11/6)
DOR BioPharma Inc. (OTC BB:DORB) Orphan Australia Pty. Ltd.* (Australia) Letter of intent for Orphan Australia to act as DOR's sponsor for administration of a Named Patient Access Program for orBec to gastro-intestinal graft-vs.-host disease patients in Australia, New Zealand and South Africa OrBec is being investigated for use in bone marrow/stem cell transplantation patients (11/28)
Eden Biodesign Ltd.* (UK) ImmunoBiology Ltd.* (UK) Extended collaboration to develop ImmBio's influenza vaccine The new contract covers a range of development and cGMP manufacturing services to produce material for ImmBio's Phase I trial (11/12)
Grant Life Sciences Inc. (OTC BB:GLIF) Alphagenics Diaco Biotechnologies Srl* (Italy) In-licensing agreement for the manufacturing and marketing rights to a molecular diagnostic test for human papilloma-viruses in Italy Grant will hold exclusive rights in all other countries (11/13)
Innovex UK Ltd.* (UK; arm of Quintiles Trans-national Corp.) PharmaMar SA (Spain subsidiary of Zeltia SA; LSE:ZEL) Agreement to recruit, train and deploy a specialized oncology sales team in Western Europe to promote Yondelis, PharmaMar's treatment for soft-tissue sarcoma PharmaMar will be responsible for marketing the drug, which was launched earlier this year in the UK and Germany (12/3)
Inspiration Bio-pharmaceuticals* Cook Pharmica* Agreement to conduct development work on a lead biologic therapy, an intravenous Factor IX product for hemophilia B Financial terms were not disclosed (11/19)
Inverness Medical Innovations Inc. (AMEX:IMA) Chemogen Inc.* Agreement for the worldwide manufacture and distribution of tests for rapidly detecting Mycobacterium Financial terms were not disclosed (11/8)
Kedrion SpA* (Italy) ProMetic Bio-Therapeutics Inc.* Agreement for multiple hyperimmunes, under which Kedrion will license tech nologies from ProMetic to enable hyperimmune manufacturing in Europe The agreement is based on license fees, service fees and royalties to be paid to ProMetic (11/8)
Orthovita Inc. (VITA) Allergan Inc. (NYSE:AGN) Agreement to acquire raw material, equipment and a technology license from Allergan Orthovita will pay $6.6M in cash; the deal relates primarily to the production of Orthovita's Vitagel Surgical Hemostat product, which combines bovine collagen and thrombin with the patient's auto-logous plasma (10/19)
Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

ASX = Australian Stock Exchange; BE = Berlin Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.